Coherus Solutions ™ offers healthcare professionals comprehensive practice and patient support that includes extensive patient assistance, industry-leading electronic services, and office support to ...
Lucentis is a prescription medication given by injection into the eye and it has side effects. Some Lucentis patients have had detached retinas and serious infections inside the eye. If the eye ...
Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...
REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), today announced that sales of CIMERLI® (ranibizumab-eqrn) to retinal specialists have exceeded 100,000 doses ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ...
August 10, 2012 — The US Food and Drug Administration (FDA) has approved ranibizumab (Lucentis, Genentech) intravitreal injection for the treatment of diabetic macular edema (DME), according to an ...
Please provide your email address to receive an email when new articles are posted on . SEATTLE — Initial experience with two ranibizumab biosimilars showed no unexpected adverse events, according to ...
An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...
– CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* – – Demonstrated safety and efficacy in clinical trials and real-world settings – – Robust and reliable supply addresses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results